Reports of STING depletion preventing cancer metastasis and long-term STING activation maintaining cancer stemness,62 promoting mesenchymal subtypes63 and treatment resistance46 highlight current knowledge gaps that need to be addressed to help ensure the safe and effective use of STING agonists in treating cancer patients.46,62,63. Here, STING1 is linked to cancer.